Medicare And CAR-Ts: Breyanzi Denied Add-On Payments But Tecartus, Abecma Approved
Executive Summary
CMS shows willingness to continue approving new technology add-on payments for CAR-T treatments despite suggestions they are no longer needed.
You may also be interested in...
Janssen Seeking Medicare Add-On Payments For CAR-T Carvykti, But CMS May Be Skeptical
J&J will need to convince the Centers for Medicare and Medicaid Services that its treatment is not substantially similar to existing CAR-T’s in order to qualify for supplemental Medicare reimbursement.
Will Production Bottlenecks For BMS’s Abecma Pose Problems After EU Approval?
BMS’s pioneering BCMA-directed CAR T-cell immunotherapy has been conditionally approved in the EU to treat certain patients with multiple myeloma, five months after getting the greenlight in the US where high demand for the drug has met production constraints.
As CAR-Ts Proliferate, CMS Seeks To Reserve Medicare Add-On Payments For ‘New’ Therapies
Products from Bristol-Myers Squibb, Gilead and J&J might be eligible for supplemental reimbursement under hospital payment proposed rule that could help promote uptake.